[1] |
HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun.
Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
|
[2] |
SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun.
Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
|
[3] |
HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle.
Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
|
[4] |
HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun.
Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
|
[5] |
LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao.
Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
|
[6] |
LIU Chen, FANG Mengdie, XU Hao, LI Chao, REN Juan, ZUO Bowen, ZHANG Yanmei.
Atractyloside targets the area of action of oncoprotein BORIS to inhibit cancer cell proliferation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1005-1013.
|
[7] |
LIU Lu, CHEN Xiaoyan.
Current status of clinical drug-drug interactions research of innovative small molecule drugs in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875.
|
[8] |
MENG Qiang, LIU Kexin.
Research status and prospect of transporter-mediated drug-drug interactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
|
[9] |
ZHOU Han, LIU Xiaodong.
Application of physiologically based pharmacokinetic model in drug development and several questions being thought
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 889-913.
|
[10] |
SUN Bo, FU Shujun, CHEN Guiliang, LI Li.
Applications of Drug Interaction Study in New Drug Development and Regulartory Decision-making
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1095-1102.
|
[11] |
TIAN Yali, FENG Lin, ZHAO Wan, GU Min, SHEN Hanjing, CHAI Xiaoyan.
Correlation of BRCA1 gene polymorphism with chemosensitivity and prognosis of metastatic esophageal squamous cell carcinoma treated with cisplatin combined with capecitabine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1118-1126.
|
[12] |
XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang.
Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
|
[13] |
WANG Xianghai, XING Min, LYU Tangfeng, LIU Hongbing, SONG Yong.
Effects of knocking down long intergenic non-coding RNA 00467 on the prognosis of patients with lung adenocarcinoma and its mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 841-849.
|
[14] |
ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie.
Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
|
[15] |
YANG Lu, WEI Bin, ZHANG Liping, BI Shanshan, LU Wei.
Response surface model to optimize the concentration range of propofol and remifentanil
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 413-420.
|